BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28254486)

  • 1. SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.
    Curtin ML; Pliushchev MA; Li HQ; Torrent M; Dietrich JD; Jakob CG; Zhu H; Zhao H; Wang Y; Ji Z; Clark RF; Sarris KA; Selvaraju S; Shaw B; Algire MA; He Y; Richardson PL; Sweis RF; Sun C; Chiang GG; Michaelides MR
    Bioorg Med Chem Lett; 2017 Apr; 27(7):1576-1583. PubMed ID: 28254486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
    He Y; Selvaraju S; Curtin ML; Jakob CG; Zhu H; Comess KM; Shaw B; The J; Lima-Fernandes E; Szewczyk MM; Cheng D; Klinge KL; Li HQ; Pliushchev M; Algire MA; Maag D; Guo J; Dietrich J; Panchal SC; Petros AM; Sweis RF; Torrent M; Bigelow LJ; Senisterra G; Li F; Kennedy S; Wu Q; Osterling DJ; Lindley DJ; Gao W; Galasinski S; Barsyte-Lovejoy D; Vedadi M; Buchanan FG; Arrowsmith CH; Chiang GG; Sun C; Pappano WN
    Nat Chem Biol; 2017 Apr; 13(4):389-395. PubMed ID: 28135237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
    Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
    Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding Modes of Small-Molecule Inhibitors to the EED Pocket of PRC2.
    Huang D; Tian S; Qi Y; Zhang JZH
    Chemphyschem; 2020 Feb; 21(3):263-271. PubMed ID: 31816138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.
    Li L; Zhang H; Zhang M; Zhao M; Feng L; Luo X; Gao Z; Huang Y; Ardayfio O; Zhang JH; Lin Y; Fan H; Mi Y; Li G; Liu L; Feng L; Luo F; Teng L; Qi W; Ottl J; Lingel A; Bussiere DE; Yu Z; Atadja P; Lu C; Li E; Gu J; Zhao K
    PLoS One; 2017; 12(1):e0169855. PubMed ID: 28072869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
    Yang CY; Wang S
    J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
    Zhu K; Du D; Yang R; Tao H; Zhang H
    Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.
    O' Donovan DH; Gregson C; Packer MJ; Greenwood R; Pike KG; Kawatkar S; Bloecher A; Robinson J; Read J; Code E; Hsu JH; Shen M; Woods H; Barton P; Fillery S; Williamson B; Rawlins PB; Bagal SK
    Bioorg Med Chem Lett; 2021 May; 39():127904. PubMed ID: 33684441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
    Huang Y; Zhang J; Yu Z; Zhang H; Wang Y; Lingel A; Qi W; Gu J; Zhao K; Shultz MD; Wang L; Fu X; Sun Y; Zhang Q; Jiang X; Zhang J; Zhang C; Li L; Zeng J; Feng L; Zhang C; Liu Y; Zhang M; Zhang L; Zhao M; Gao Z; Liu X; Fang D; Guo H; Mi Y; Gabriel T; Dillon MP; Atadja P; Oyang C
    J Med Chem; 2017 Mar; 60(6):2215-2226. PubMed ID: 28092155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response.
    Dong H; Liu S; Zhang X; Chen S; Kang L; Chen Y; Ma S; Fu X; Liu Y; Zhang H; Zou B
    Cancer Res; 2019 Nov; 79(21):5587-5596. PubMed ID: 31395608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.
    Rej RK; Wang C; Lu J; Wang M; Petrunak E; Zawacki KP; McEachern D; Fernandez-Salas E; Yang CY; Wang L; Li R; Chinnaswamy K; Wen B; Sun D; Stuckey J; Zhou Y; Chen J; Tang G; Wang S
    J Med Chem; 2020 Jul; 63(13):7252-7267. PubMed ID: 32580550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2.
    Barnash KD; The J; Norris-Drouin JL; Cholensky SH; Worley BM; Li F; Stuckey JI; Brown PJ; Vedadi M; Arrowsmith CH; Frye SV; James LI
    ACS Comb Sci; 2017 Mar; 19(3):161-172. PubMed ID: 28165227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
    Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
    J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel class of potent human deoxyuridine triphosphatase inhibitors remarkably enhancing the antitumor activity of thymidylate synthase inhibitors.
    Miyahara S; Miyakoshi H; Yokogawa T; Chong KT; Taguchi J; Muto T; Endoh K; Yano W; Wakasa T; Ueno H; Takao Y; Fujioka A; Hashimoto A; Itou K; Yamamura K; Nomura M; Nagasawa H; Shuto S; Fukuoka M
    J Med Chem; 2012 Apr; 55(7):2970-80. PubMed ID: 22339362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery, design, and synthesis of indole-based EZH2 inhibitors.
    Gehling VS; Vaswani RG; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Dakin LA; Cook AS; Gagnon A; Harmange JC; Audia JE; Cummings RT; Normant E; Trojer P; Albrecht BK
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3644-9. PubMed ID: 26189078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
    Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
    J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.
    Tomassi S; Romanelli A; Zwergel C; Valente S; Mai A
    J Med Chem; 2021 Aug; 64(16):11774-11797. PubMed ID: 34351144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.
    Bao Q; Kumar A; Wu D; Zhou J
    Drug Discov Today; 2024 Jun; 29(6):103986. PubMed ID: 38642703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
    Catalano R; Rocca R; Juli G; Costa G; Maruca A; Artese A; Caracciolo D; Tagliaferri P; Alcaro S; Tassone P; Amodio N
    Eur J Med Chem; 2019 Dec; 183():111715. PubMed ID: 31550663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.